Article
External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
Virchows Archiv : an international journal of pathology - 1 Feb 2023
Esposito Abate Riziero, Cheetham Melanie H, Fairley Jennifer A, Pasquale Raffaella, Sacco Alessandra, Nicola Wolstenholme, Deans Zandra C, Patton Simon J, Normanno Nicola
Abstract excerpt
Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods for TMB testing have not yet been standardized. The International Quality Network for Pathology (IQNPath) organized a pilot external quality assessment (EQA) scheme for TMB testing. The aim of this program was the validation of the materials and the procedures for the EQA of this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
